Accord received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for ...

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and ...

Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in ...

The agreement gives Samsung Bioepis exclusive rights to another three products in phase 3 testing, including biosimilars of AstraZeneca/Alexion's Soliris (eculizumab), Amgen's Prolia (denosumab ...

China & JERSEY CITY, N.J., October 30, 2024--Henlius and Organon announced US FDA has accepted the Biologics License Application (BLA) for HLX14, biosimilar candidate of PROLIA/XGEVA (denosumab).

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...